“Kovax, currently there is no plan to reject AZ vaccine”

Input 2021.02.09 08:28

“South African mutation research in progress”
“Vaccine Discarded, Still Early”

Reuters reported on the 8th (local time) that the international project’Covax Facility’ for the joint purchase of vaccines indicated that there is currently no plan to reject AstraZeneca’s novel coronavirus infection (Corona 19) vaccine.

Seth Berkeley, CEO of the Global Vaccine and Immunity Alliance (GAVI), which leads COVAX along with the World Health Organization (WHO) and the Infectious Disease Innovation Association (CEPI), said, “The preventive effect of AstraZeneca vaccine against the corona 19 mutant virus originating in South Africa. “The research is still ongoing.”

“It is absolutely important to use our tools as effectively as possible,” said CEPI President Richard Hachet. “It is too early to dispose of the vaccine.”

There was also a discussion that the effect could be enhanced by increasing the interval between the 1st and 2nd vaccinations, which is currently 4 weeks, to 12 weeks.

“Today (8th) WHO’s immunization advisory group, the Expert Strategy Advisory Group (SAGE), gathered to review AstraZeneca vaccine,” said WHO Secretary General Thewardros Adhanom Gobrersusus. Tomorrow (9th) I will meet the chairman of SAGE.”

Previously, a research team at Oxford University in the UK and South Africa showed that the vaccine did not prevent mild and moderate symptoms caused by mutations in South Africa, and the preventive effect was only 10%. Based on this, the South African government suspended the use of the vaccine the day before.